Cimzia® (certolizumab pegol) – New indication
March 28, 2019 - The FDA announced the approval of UCB’s Cimzia (certolizumab pegol), for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.
Download PDF
